NOTE: Reconstitution must be done with Acetic Acid. AOD-9604 Description AOD-9604 is a research peptide consisting of amino acids 177–191 of the human growth hormone sequence. Studies indicate it modulates lipid and glucose metabolism pathways without influencing IGF-1 activity, acting primarily through β-adrenergic and AMPK-related mechanisms. It is commonly used in metabolic and adipocyte differentiation research to elucidate downstream energy regulation signaling. Peptide Information Property Value Peptide Sequence H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH Molecular Formula C78H123N23O23S2 Molecular Weight 1815.1 g/mol CAS Number 221231-10-3 PubChem CID 71300630 Synonyms AOD-9604, AOD 9604 AOD9604 Research 1. AOD9604 and Obesity This peptide was originally created as a modified growth hormone fragment with the primary goal of assisting weight management. In mid-stage clinical work involving a sizeable group of adults with obesity, once-daily dosing over several weeks produced greater average weight reduction compared to placebo, and the pace of weight loss remained steady throughout the observation period. These findings suggest that the body does not quickly adapt to or resist its effects, raising the possibility that extended use under appropriate conditions could lead to more substantial fat loss. 2. Joint Pain and Function Preclinical research in animals with experimentally induced joint degeneration has shown that injecting AOD9604 directly into affected joints can complement existing treatments. In these models, the peptide has been associated with reduced pain-related behaviors, improved mobility, and measurable changes in cartilage structure that are consistent with healthier joint tissue. Although it appears to have beneficial effects on its own, outcomes are often better when AOD9604 is combined with other joint-supporting therapies, suggesting a synergistic potential and pointing to new avenues for exploring cartilage repair strategies. 3. AOD9604 and Heart Health While reducing excess fat and body weight is known to lower cardiovascular risk, investigations suggest that AOD9604 may have additional influences on metabolic processes that are relevant to heart health. Some findings indicate that it could improve certain metabolic markers independently of its role in fat loss, similar to how other compounds can modify metabolic risk factors without necessarily causing weight reduction. The alternative pathways through which AOD9604 promotes changes in fat tissue, beyond beta-3 adrenergic receptor activity, are of particular interest for their potential impact on broader metabolic balance. In animal testing, AOD9604 has generally shown a favorable tolerability profile, with good absorption when given orally and effective uptake when administered by injection. Dosages used in animal experiments cannot be directly translated to appropriate amounts for human use. This compound is intended strictly for controlled laboratory and scientific research and is not approved for human consumption or therapeutic application. For Research Use OnlyThis compound is provided exclusively for in vitro laboratory research. It is not intended for human or animal consumption, diagnosis, treatment, or medical use. Not for dietary, cosmetic, or veterinary purposes. This product has not been evaluated by the U.S. Food and Drug Administration or any other regulatory authority. DisclaimerAll information is for educational purposes only. Humatide makes no claims regarding efficacy or safety. Purchasers are responsible for ensuring proper handling and use in compliance with all applicable laws and regulations. Terms of SaleBy purchasing from Humatide, you confirm that you are a qualified researcher with the knowledge and facilities to safely handle and store research chemicals. All sales are final. Humatide assumes no liability for misuse, misrepresentation, or unintended consequences arising from the use of this product.
Related
Related
Related
Related